SCHEMBL25819511

SCHEMBL25819511

O=C(O)CCNc1ccc(N2CCC(CN3CCC4(CC3)CC(NC(=O)OCc3ccccc3)C4)CC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 4/20 0.44
CPB1 P15086 1/20 0.41
SYK P43405 1/20 0.40
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSK P43235 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
F13A1 P00488 3/20 0.39
TGM2 P21980 3/20 0.39
TGM1 P22735 3/20 0.39
ENPP2 Q13822 1/20 0.39
ATXN2 Q99700 1/20 0.39
DPP4 P27487 1/20 0.39
KCNH2 Q12809 1/20 0.39
DPP7 Q9UHL4 1/20 0.39
TSHR P16473 1/20 0.38
HTR1A P08908 1/20 0.38
DRD2 P14416 1/20 0.38
HTR2A P28223 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25819512 0.87 CHRM4 (0.48) CHRM4SYKCTSLCTSBCTSK
SCHEMBL25819513 0.84 CHRM4 (0.44) CHRM4CTSLCTSBCTSKALDH1A1
SCHEMBL30965642 0.82 CHRM4 (0.44) CHRM4CTSLCTSBCTSKALDH1A1
SCHEMBL25819521 0.82 CHRM4 (0.45) CHRM4CTSLCTSBCTSKALDH1A1
SCHEMBL25819509 0.82 CHRM4 (0.44) CHRM4SYKCTSLCTSBCTSK
SCHEMBL30135824 0.80 SYK (0.43) CHRM4SYKCTSLCTSBCTSK
SCHEMBL30135811 0.79 DPP4 (0.42) CHRM4CPB1CTSLCTSBCTSK
SCHEMBL25819522 0.79 CHRM4 (0.43) CHRM4CTSLCTSBCTSKALDH1A1
SCHEMBL25819515 0.79 ALDH1A1 (0.47) CTSLCTSBCTSKALDH1A1GAA
SCHEMBL30135818 0.78 ENPP2 (0.42) CHRM4CTSLCTSBCTSKALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 CHRM4 4481/4885CPB1 2246/4885SYK 3825/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 CHRM4 4192/4885CPB1 2590/4885SYK 3406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.